Synthetic PPARγ agonists, including the antidiabetic drugs thiazolidinediones (TZDs), demonstrated to induce growth inhibition, apoptosis, and differentiation of breast cancer cells in in vitro and in vivo models [18]. This evidence concerns the gene PPARG and breast cancer.